Author/Authors :
Jianguo Cao، نويسنده , , Richard Fine، نويسنده , , Colleen Gritzen، نويسنده , , John Hood-Williams، نويسنده , , Xinshan Kang، نويسنده , , Boris Klebansky، نويسنده , , Dan Lohse، نويسنده , , Chi Ching Mak، نويسنده , , Andrew McPherson، نويسنده , , Glenn Noronha، نويسنده , , Moorthy S.S. Palanki، نويسنده , , Ved P. Pathak، نويسنده , , Joel Renick، نويسنده , , Richard Soll، نويسنده , , Binqi Zeng، نويسنده , , Hong Zhu، نويسنده ,
Abstract :
We describe the design, synthesis and structure–activity relationship studies in optimizing a series of benzotriazine compounds as potent inhibitors of both Abl and Abl-T315I enzymes. The design includes targeting of an acid functional residue on the αC-helix that is available only upon kinase activation. This designed interaction provides an advantage in overcoming the challenges arising from the T315I mutation of Abl and transforms poor (ca. 10 μM) inhibitors into those with low nM potency.
Keywords :
Abl inhibitor , Abl-T315I , BCR-ABL , cancer , kinase inhibitor , CML , Benzotriazines , Chronic myeloid leukemia